{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dopamine
to a specific field?
Status:
Investigational
Source:
NCT04714359: Phase 3 Interventional Completed PTSD
(2021)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Methylenedioxymethamphetamine (or 3,4-methylenedioxymethamphetamine (MDMA)), a synthetic, psychoactive drug also known as ecstasy that was used as a recreational drug. This drug acts as both a stimulant and psychedelic and exerts its effects in the brain on neurons that use the chemicals serotonin, dopamine and norepinephrine to communicate with other neurons. In spite of the presence of this compound in the List of control and forbidden compounds, it was studied in psychotherapy for patients with chronic, treatment-resistant posttraumatic stress disorder. Initial results showed efficacy for the treatment approach, although further studies are needed.
Status:
Investigational
Source:
NCT01094821: Phase 1/Phase 2 Interventional Completed Healthy
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Naronapride (ATI-7505), an orally administered, cisapride analogue and serotonin4 (5HT4) receptor agonist, is being developed by Renexxion for the treatment of multiple gastrointestinal disorders. Sinovant is initially developing naronapride for the treatment of irritable bowel syndrome – constipation (IBS-C), a disease that affects millions of Chinese patients and for which few effective treatment options are available. Naronapride has been evaluated in over 900 subjects in multiple randomized controlled clinical studies and has demonstrated promising results in patients with gastroesophageal reflux disease (GERD), erosive esophagitis (EE), and chronic idiopathic constipation (CIC). Naronapride’s low systemic absorption and high specificity for 5HT4 and D2 receptors is thought to improve its safety and tolerability profile relative to other members of the class.
Status:
Investigational
Source:
INN:levofacetoperane [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Levophacetoperane is a piperidine derivative. Levofacetoperane is a sympathomimetic central nervous system stimulant and is commonly used to treat depression. Levophacetoperane is also a known analeptic and is strongly linked to apnea reversal in dogs after a single intravenous injection.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Delergotrile is a derivative of ergot alkaloids with dopaminergic and anti-parkinsonian action. Delergotine shows neuropharmacological action typical of postsynaptic dopamine D1 receptor stimulants, in particular in the extrapyramidal system. In addition, delergotine stimulates adenylate cyclase coupled serotonin receptors and antagonize central alpha-adrenergic receptors. The compound was studied in the clinical trials, in new, non-levodopa-treated parkinsonian patients. Delergotine elicited a significant but mostly only mild or moderate antiparkinsonian efficacy which seems to be less than that of levodopa.
Class (Stereo):
CHEMICAL (EPIMERIC)
Cianergoline is an ergoline derivative with marked dopaminergic agonist and a predominant cardiovascular action patented by Farmitalia Carlo Erba S.p.A for hypertension treatment. The preclinical evaluation shows dose-related hypotensive effects after single oral, intraduodenal and intravenous administration of Cianergoline in cats, dogs, and rats. Cianergoline showed a prompt onset of action and a prolonged effect on blood pressure at low doses without substantially modifying animals heart rate. One month daily oral administration of Cianergoline in rats produced an antihypertensive effect persisting through the entire experiment with no signs of tachyphylaxis. Unfortunately, in clinical trials Cianergoline caused a slight, statistically non-significant blood pressure lowering effect in patients with essential hypertension and does not modify the release of prolactin, lipid metabolism or the basal activity or postural responsiveness of the renin-angiotensin-aldosterone axis and of the sympathetic nervous system.
Class (Stereo):
CHEMICAL (RACEMIC)
Sulverapride is a methylsulfamoylbenzamide derivative patented by Societe d'Etudes Scientifiques et Industrielles de l'Ile-de-France for the treatment of lower urinary tract disorders
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Spiramide (AMI-193) is a spiperone derivative, a selective 5-HT2A, (Ki = 2 nM) 5-HT1A (Ki = 50 nM), and D2 receptor (Ki = 3 nM) antagonist, with negligible affinity for the 5-HT2C receptor (Ki = 4300 nM). The ability of Spiramide to serve as a functional 5-HT2A antagonist in behavioral studies was demonstrated through studies in which Spiramide blocked the discriminative - stimulus effects of the 5HT2A agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM).
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine ((-)-3-PPP, also known as preclamol) has a dual action towards to dopamine D2 autoreceptor: it activates it and also acts concomitantly as an antagonist at postsynaptic DA receptors. It was shown, that (-)-3PPP/preclamol was a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy. Besides, the motor effects of the drug were evaluated in nine patients with Parkinson's disease using a double-blind, placebo-controlled design. However, the small number of patients manifesting a clinically significant response and the frequently inconsistent effects could indicate that this class of agents may have relatively limited clinical utility.
Status:
Investigational
Source:
NCT03845075: Phase 2 Interventional Completed Hypothalamic Injury-induced Obesity (HIO)
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Tesofensine (also known as NS-2330) is a novel triple monoamine reuptake inhibitor with intrinsic inhibitory activity on norepinephrine (NE), serotonin (5-HT), and dopamine (DA) transporter function. It was development by NeuroSearch as a potential therapy for Alzheimer's disease (AD) and Parkinson's diseases, but these efforts have been discontinued. In phase II clinical trials with tesofensine in obese individuals, dose-related reductions in body weight, body fat and waist circumference, as well as improvements in other obesity-related endocrine factors were observed and the FDA recently endorsed the phase III trial program for this agent.
Status:
Investigational
Source:
INN:mespiperone (¹¹C) [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Mespiperone C-11 (3-N-[11C] methylspiperone) is a radiolabeled 3-N-methylspiperone. 3-N-methylspiperone is high-affinity D2/3 dopamine and 5-HT2A serotonin receptor antagonist. It has been studied as a positron emission tomography (PET) tracer for imaging D2/3 and 5HT2A receptor densities.
